These young biotech entrepreneurs are looking to make billions by editing life itself: by mtindera07
with another Crispr pioneer, 37-year-old Feng Zhang of the Broad Institute of MIT and Harvard.
Crispr is an acronym for “clustered regularly interspaced short palindromic repeats.” It refers to the way bacteria store, in their genomes, snippets of viral DNA, like mug shots. Those markers are used to identify invaders that return, much as a human immune system uses telltale elements of a polio virus remembered from a vaccine.
Haurwitz grew up in Austin, Texas, and earned a bachelor’s degree in biology at Harvard. She didn’t have a clear plan when she went on to UC Berkeley, but she thought she might later become a patent attorney. Haurwitz took a few business classes before getting her Ph.D., then pitched venture capitalists on funding a technology they didn’t really understand. Caribou was securing an exclusive license to some Crispr patents held by the University of California system and the University of Vienna. Still, “pretty much every VC we talked to kind of said, ‘Meh,’ ” Haurwitz remembers. This was 2012, and they thought she was overestimating Crispr’s potential.
Caribou licensed to Integrated DNA Technologies the right to sell biology researchers what they’d need for gene-editing experiments. Genus, an animal genetics firm, paid Caribou an undisclosed amount for the exclusive right to use its proprietary Crispr technology to engineer the genes of pigs and other livestock. Similarly, the Jackson Laboratory is paying Caribou to use Crispr to engineer new populations of research mice that model human diseases.
Beyond the competition, there is an intellectual property conflict. Overlapping patent claims from the University of California and the Broad Institute emerged for the foundational technology, which involves an enzyme called Cas9, used to cut DNA. A lawsuit between the institutions was decided in favor of the Broad, but the U.S. Patent Office has granted patents to both.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Gene Hackers: The Young Biotech Entrepreneurs Looking To Make Billions By Editing Life ItselfEntrepreneurs are taking genetic-editing technology from the lab to the clinic with grand ambitions. But who owns the patents?
Weiterlesen »
Gene Hackers: The Young Biotech Entrepreneurs Looking To Make Billions By Editing Life ItselfEntrepreneurs are taking genetic-editing technology from the lab to the clinic with grand ambitions. But who owns the patents? by mtindera07
Weiterlesen »
Gene Hackers: The Young Biotech Entrepreneurs Looking To Make Billions By Editing Life ItselfEntrepreneurs are taking genetic-editing technology from the lab to the clinic with grand ambitions. But who owns the patents?
Weiterlesen »
Roche pushes back Spark takeover again as regulatory review drags onSwiss drugmaker Roche is pushing back its $4.3 billion takeover offer for gene t...
Weiterlesen »
Breakingviews - Three reasons a wonder drug can cost $5 mln(Reuters Breakingviews) - Novartis's gene therapy for spinal muscular atrop...
Weiterlesen »
Commentary: Novartis CEO says gene therapies promise to upend US health system, pricing structureThe current global health system treats chronic diseases with a pay-as-you-go model, spreading costs over months and years. It's unprepared to pay for a surge of new, single-treatment therapies with the potential to provide a lifetime of benefit.
Weiterlesen »
Lawbreakers to lawmakers? The 'criminal candidates' standing in India's electionThe Bharatiya Janata Party (BJP) has one unwanted lead in this month's gene...
Weiterlesen »
Gene Simmons delivers briefing at Pentagon podium that has not seen a spokesperson in almost a yearKISS frontman Gene Simmons conducted only the second on-camera press briefing at the Department of Defense in the past year. The last person to stand at the podium was movie star Gerard Butler, who was there in October to promote a new movie.
Weiterlesen »
Three reasons a wonder drug can cost $5 mlnNovartis’s gene therapy for a deadly disease looks likely to set a record. There are justifiable factors, like the value it delivers and drugmakers’ high development costs. Then there are less palatable ones, including an inefficient U.S. market with a tolerance for high prices.
Weiterlesen »
The Unfulfilled Promise of DNA TestingGenetic testing provides families and doctors a wealth of new information. But the medical world is making rapid advances in understanding what the data means, and that’s whipsawing diagnoses and treatment.
Weiterlesen »